Key Takeaways
- The New York Mets recalled veteran infielder Jorge Polanco from a minor‑league rehab assignment with Triple‑A Syracuse for additional testing on his right ankle after he reported soreness.
- Polanco is currently on the injured list for a right‑wrist contusion and left‑Achilles bursitis, originally placed on the list on April 15.
- Since signing a two‑year, $40 million contract in the offseason to replace Pete Alonso as the team’s primary power bat, Polanco has appeared in only 14 games, posting a .179 batting average with one home run and two RBIs.
- This marks his seventh stint on the injured list since the 2022 season, underscoring a pattern of recurring health issues that have limited his availability and effectiveness.
- The Mets’ decision to bring him back to New York for further evaluation reflects both caution over his ankle and the organization’s need to clarify his status as they navigate a competitive NL East race.
The New York Mets announced on Saturday that they have recalled Jorge Polanco from his minor‑league rehab stint with Triple‑A Syracuse to undergo additional medical evaluation on his right ankle. The move came after Polanco informed the club that he was experiencing soreness in the joint, prompting the Mets to prioritize a more thorough assessment rather than allowing him to continue playing at the Triple‑A level while the issue remained unresolved.
Polanco’s current placement on the injured list stems from two separate ailments: a right‑wrist contusion and left‑Achilles bursitis, both of which landed him on the IL on April 15. Initially, the plan had been for him to continue his rehabilitation in Syracuse, where he could work toward regaining game‑ready condition before a potential return to the major‑league roster. However, the emergence of ankle discomfort altered that trajectory, leading the front office to bring him back to New York for imaging, specialist consultation, and a structured treatment plan.
At 32 years old, Polanco signed a two‑year, $40 million contract during the offseason with the explicit purpose of serving as the Mets’ replacement for the departed Pete Alonso in the middle of the order. The deal signaled the organization’s confidence in his ability to provide both left‑handed power and switch‑hitting versatility. Yet, to date, the return on that investment has been modest. Across 14 appearances, Polanco is batting a modest .179 with a single home run and just two runs batted in. His offensive output has fallen well short of the expectations attached to his contract, and his limited playing time has further hampered his ability to find a rhythm at the plate.
The ankle issue is the latest in a series of health setbacks that have plagued Polanco since the 2022 season. This current stint represents his seventh trip to the injured list over roughly a three‑year span, a pattern that raises concerns about his durability and long‑term viability as an everyday contributor. Prior injuries have included wrist sprains, hamstring strains, and various lower‑body ailments, each of which has forced the Mets to adjust their lineup and rely on internal options or bench players to fill the gap.
From a managerial perspective, Polanco’s recurring health problems complicate roster construction. The Mets are currently engaged in a tight battle for a playoff spot in the National League East, where every game and every at‑bat carries heightened importance. The coaching staff must weigh the risk of rushing Polanco back prematurely against the potential benefit of having a veteran switch‑hitter available for late‑inning pinch‑hit situations or as a defensive replacement at second or third base. The additional testing now underway will help clarify whether the ankle soreness is a minor irritation that can be managed with rest and treatment, or if it signals a more significant structural problem that could necessitate a longer absence or even surgery.
Financially, the situation also carries weight. Polanco’s $20 million average annual value represents a sizable chunk of the Mets’ payroll, and his inability to stay on the field impacts the team’s ability to maximize return on that investment. If the ankle issue proves chronic, the front office may need to explore alternatives—such as pursuing a trade, promoting a prospect from the minors, or adjusting the lineup to accommodate other players who can provide similar offensive production.
In the interim, the Mets will likely rely on a combination of internal candidates—such as J.D. Davis, Luis Guillorme, or a call‑up from Syracuse—to cover the infield spots Polanco would normally occupy. The organization’s medical and training staff will continue to monitor his progress closely, providing updates as more information becomes available from the ankle evaluation.
Overall, Polanco’s recall for further testing underscores the precarious balance the Mets must strike between patient rehabilitation and the urgent need for productive contributions in a competitive season. The outcome of the ankle assessment will not only shape Polanco’s immediate future with the club but also influence broader roster decisions as the Mets strive to stay in contention for a postseason berth.